# Subcutaneous Ig NextGen 16% in PID Patients

> **NCT00391131** · PHASE3 · COMPLETED · sponsor: **CSL Limited** · enrollment: 35 (actual)

## Conditions studied

- Primary Immunodeficiency (PID)

## Interventions

- **DRUG:** IgNextGen 16%

## Key facts

- **NCT ID:** NCT00391131
- **Lead sponsor:** CSL Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** 2009-10
- **Final completion:** 2009-10
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2012-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00391131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00391131, "Subcutaneous Ig NextGen 16% in PID Patients". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00391131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*